- Home
- URGN vs QTRX Comparison
URGN vs QTRX Comparison
Compare URGN & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- QTRX
- Stock Information
- Founded
- URGN 2004
- QTRX 2007
- Country
- URGN United States
- QTRX United States
- Employees
- URGN N/A
- QTRX N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- QTRX Biotechnology: Laboratory Analytical Instruments
- Sector
- URGN Health Care
- QTRX Industrials
- Exchange
- URGN Nasdaq
- QTRX Nasdaq
- Market Cap
- URGN 547.1M
- QTRX 439.1M
- IPO Year
- URGN 2017
- QTRX 2017
- Fundamental
- Price
- URGN $11.19
- QTRX $11.44
- Analyst Decision
- URGN Strong Buy
- QTRX Strong Buy
- Analyst Count
- URGN 5
- QTRX 4
- Target Price
- URGN $44.50
- QTRX $23.25
- AVG Volume (30 Days)
- URGN 456.4K
- QTRX 462.6K
- Earning Date
- URGN 11-06-2024
- QTRX 11-12-2024
- Dividend Yield
- URGN N/A
- QTRX N/A
- EPS Growth
- URGN N/A
- QTRX N/A
- EPS
- URGN N/A
- QTRX N/A
- Revenue
- URGN $89,363,000.00
- QTRX $129,330,000.00
- Revenue This Year
- URGN $14.43
- QTRX $13.56
- Revenue Next Year
- URGN $44.44
- QTRX $16.49
- P/E Ratio
- URGN N/A
- QTRX N/A
- Revenue Growth
- URGN 15.64
- QTRX 15.52
- 52 Week Low
- URGN $10.60
- QTRX $10.50
- 52 Week High
- URGN $20.70
- QTRX $29.70
- Technical
- Relative Strength Index (RSI)
- URGN 35.94
- QTRX 35.72
- Support Level
- URGN $11.93
- QTRX $14.72
- Resistance Level
- URGN $12.78
- QTRX $15.46
- Average True Range (ATR)
- URGN 0.71
- QTRX 0.96
- MACD
- URGN -0.05
- QTRX -0.27
- Stochastic Oscillator
- URGN 1.36
- QTRX 4.94
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory, Homebrew - Custom Assay Development, and Uman NF-Light.